Pharma Focus Asia

Astellas Pharma Plans to Construct New Manufacturing Lines for Aseptic Drug Products

Astellas Pharma Inc plans to construct new manufacturing linesfor aseptic drug products with an investment of US$16 million(¥18 billion). It will be located at Yaizu Technology Center of Astellas Pharma Tech Co., Ltd.


The manufacturing facility for drug products covers an area of 8,000m2along with an investigational drug production line which includes an area of 1,800m2.

The production lines will use new modalities and latest technologies to speed up the development and commercialisation of new drugs.

The newly installed aseptic drug product manufacturing lineswill be used for commercial antibody drugs and clinical trial materials in the current building.

The production lines designed for aseptic drug products not only allowflexible manufacturing of drug products but alsoconsists of new modalities in the facility with high technology.
It is expected that the construction of new drug manufacturing facility will begin in January 2021 and complete in February 2022. On the other hand, the construction of investigational drug production line will start in July 2021 and expected to complete by August 2022.


NameAstellas Pharma Inc
TypeNew Construction
BudgetUS$16million (¥18 billion)
YearAugust 2022
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference